GlassScriptPhysician profile
Mansoora A Sheikh
NPI 1841389020
$2,280.40
in general payments reported to CMS, 2019-2025
20 companies · $502 in 2025
The $502 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $235 · 2020: $185 · 2021: $81.21 · 2022: $175 · 2023: $596 · 2024: $507 · 2025: $502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,604.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,604.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $497.91 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $369.67 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $284.33 | 2023-2024 | Qulipta, Ubrelvy |
| Pfizer INC. | $148.76 | 2020-2025 | |
| Lilly USA, LLC | $147.81 | 2019-2023 | Mounjaro |
| Amarin Pharma, INC. | $146.09 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $119.10 | 2025 | Zoryve |
| Astellas Pharma US INC | $102.31 | 2022 | |
| Amgen INC. | $70.50 | 2020-2024 | Repatha, Otezla |
| Inspire Medical Systems, INC. | $61.24 | 2023-2024 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.50 | 2023-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $48.76 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $40.58 | 2023 | |
| Exact Sciences Corporation | $39.08 | 2024-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $37.61 | 2021-2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $25.82 | 2025 | Sapien 3 Ultra Resilia |
| Mylan Specialty L.P. | $24.13 | 2019 | |
| Lundbeck LLC | $21.89 | 2023 | Rexulti |
| Abbott Laboratories | $21.37 | 2022 | |
| Glaxosmithkline, LLC. | $18.94 | 2024 | Arexvy, Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mansoora Sheikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.